OncoMatch/Clinical Trials/NCT06751589
A Study of a Weight Loss Intervention in People With Endometrial Cancer
Is NCT06751589 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Tirzepatide for endometrial cancer.
Treatment: Tirzepatide — The researchers are doing this study is to find out whether tirzepatide and semaglutide are practical (feasible) for weight management and blood sugar control for endometrial cancer patients undergoing chemotherapy. The researchers will also look at participants' experience with the study drug, the safety of taking the study drug while receiving chemotherapy, and changes in weight, body fat composition, and blood pressure of participants.
Check if I qualifyExtracted eligibility criteria
Cancer type
Endometrial Cancer
Disease stage
Required: Stage I, II, III
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: surgery
Completed surgery with TH/BSO with no gross residual disease
Cannot have received: surgical, endoscopic, and/or device-based therapy for obesity
Patients with a prior surgical, endoscopic, and/or device-based therapy (for example, mucosal ablation, gastric artery embolization, intragastric balloon and duodenojejunal bypass sleeve) for obesity within the past two years
Cannot have received: device-based therapy for obesity
Patients with removal of device-based therapy for obesity within the last 6 months
Lab requirements
Kidney function
Creatinine clearance (per Cockcroft-Gault formula) ≥30 mL/min
Liver function
ALT and AST ≤3.0 × ULN; total serum bilirubin ≤ 1.5 × ULN except for patients with Gilbert's syndrome who may be included if the total serum bilirubin is ≤3.0 × ULN or direct bilirubin ≤ 1.5 × ULN
Patient has adequate organ function, as defined by the following laboratory values: Creatinine clearance (per Cockcroft-Gault formula) ≥30 mL/min ... ALT and AST ≤3.0 × ULN. Total serum bilirubin ≤ 1.5 × ULN except for patients with Gilbert's syndrome who may be included if the total serum bilirubin is ≤3.0 × ULN or direct bilirubin ≤ 1.5 × ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Basking Ridge · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth · Middletown, New Jersey
- Memorial Sloan Kettering Bergen · Montvale, New Jersey
- Memorial Sloan Kettering Commack · Commack, New York
- Memorial Sloan Kettering Westchester · Harrison, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify